The citation I posted is the black box warning placed on the prescription pamphlets.
In that particular citation you shared from Healthline doesn't mention anything about a family history of medullary thyroid cancer/ multiple endocrine neoplasia s2. It briefly mentions colon cancer.
If there's a relative risk with a family history, and you're comfortable knowing there's a greater risk than the general population. As small as it may be, go for it.
As useless as I find using Healthline as a source of credibility. Its like citing Wikipedia.
This is from a different Healthline article:
"
One downside, however, is that they have not been recommended for use in those with a personal or family history of either medullary thyroid cancer or multiple endocrine neoplasia.
Previous studies, starting with rodent studies conducted in the premarketing phase, have raised concerns about whether GLP-1 receptor agonists could increase a person’s risk for cancer.
In response, these medications have been required to carry a black box warning regarding the potential risk.
However, a new studyTrusted Source published on April 10, 2024, in BMJ indicates these concerns may be unfounded.
According to this study, treatment with GLP-1 receptor agonists was not linked with any substantial increase in risk for thyroid cancer in people who were followed up on average for 3.9 years.
The study authors did acknowledge that a small increase in risk could not be ruled out, but it would be no greater than a 31% increase in relative risk.
In other words, no more than 0.36 excess cancers per 10,000 person-years would occur compared to the background incidence of 1.46 per 10,000 person-years in those who had used a different type of diabetes medication."
New research suggests that GLP-1 drugs like Ozempic and Wegovy are not likely to increase the risk of thyroid cancer.
www.healthline.com